Last updated: February 24, 2026
What is Verapamil ER PM?
Verapamil ER PM is an extended-release formulation of verapamil, a calcium channel blocker used mainly for hypertension, angina pectoris, and certain arrhythmias. It is marketed as a proprietary or generic product, depending on the entity and region.
Market Size and Key Players
Global Market Overview
The global calcium channel blocker market was valued at approximately USD 4.3 billion in 2022. Verapamil products constitute roughly 15% of this segment, with a significant portion accounted for by ER formulations, including Verapamil ER PM.
Regional Distribution
- United States: Largest market, driven by high hypertension prevalence. Estimated Verapamil ER PM sales in the US reached USD 150 million in 2022.
- Europe: Second largest, with estimated sales of USD 70 million.
- Asia-Pacific: Growing due to increasing hypertensive patients, with sales around USD 50 million.
Major Manufacturers
- AstraZeneca (legacy)
- Pfizer
- Teva Pharmaceuticals
- Mylan
- Generic companies in India and China
Patent and Patent Expirations
The original patent for Verapamil ER formulations expired between 2012-2015 in major markets, resulting in a surge of generic entries, which influence pricing and market share.
Pricing Dynamics
Historical Pricing Trends
- Brand Name (e.g., Calan ER): Was priced around USD 2.50 per tablet (100 mg).
- Generics: Price decreased by approximately 40-50% post-patent expiry, settling around USD 1.25 per tablet in the US market.
Current Price Range
- Brand Name: USD 2.50 – USD 3.00 per tablet (100 mg).
- Generics: USD 0.70 – USD 1.50 per tablet (100 mg), depending on manufacturing, packaging, and distribution channels.
Pricing Factors
- Regulatory environment
- Competition intensity
- Manufacturing costs
- Formulation complexity
- Distribution reach
Market Trends and Drivers
Growth Drivers
- Increasing prevalence of hypertension and cardiovascular diseases.
- Aging population globally.
- Rising adoption of generic medications to reduce healthcare costs.
- Patent expirations opening markets for generics.
Challenges
- Price pressure from generics and biosimilars.
- Regulatory hurdles in emerging markets.
- Competition from alternative drug classes (e.g., ACE inhibitors, ARBs).
Future Growth Opportunities
- Expansion into emerging markets.
- Development of combination therapies.
- Implementation of value-added features like dose flexibility.
Price Projection (2023-2027)
| Year |
US Price (USD per tablet) |
Europe Price (USD per tablet) |
Asia-Pacific Price (USD per tablet) |
| 2023 |
0.80 – 1.50 |
0.80 – 1.80 |
0.70 – 1.30 |
| 2024 |
0.85 – 1.60 |
0.85 – 1.90 |
0.75 – 1.40 |
| 2025 |
0.90 – 1.75 |
0.90 – 2.00 |
0.80 – 1.50 |
| 2026 |
0.95 – 1.80 |
0.95 – 2.10 |
0.85 – 1.60 |
| 2027 |
1.00 – 2.00 |
1.00 – 2.20 |
0.90 – 1.70 |
Pricing is expected to stabilize as market saturation occurs, with marginal decreases likely in price-sensitive regions.
Key Takeaways
- The global Verapamil ER PM market was approximately USD 150 million in the US in 2022.
- Post-patent expirations led to significant price declines; generics dominate pricing.
- Future sales growth depends on hypertension prevalence, generic competition, and regulatory factors.
- Prices in the US are roughly USD 0.70 – USD 1.50 per tablet, with regional variations.
- Market expansion into emerging economies and formulation innovations offer growth potential.
FAQs
1. How does patent expiry affect Verapamil ER PM pricing?
Patent expiry allows generic manufacturers to enter the market, increasing competition and reducing prices.
2. What regions present the most significant growth opportunities?
Emerging markets in Asia-Pacific and Latin America have the highest growth potential due to rising chronic disease prevalence.
3. Are there any recent regulatory changes impacting Verapamil ER PM?
Regulatory agencies have streamlined approval processes for generics, lowering barriers—and prices—post-expiry.
4. What factors influence Verapamil ER PM's market share?
Pricing, formulary inclusion, physician preferences, and insurance coverage are primary drivers.
5. How might new formulation technologies impact future prices?
Innovations like tamper-proof or combination formulations can command premium prices, potentially offsetting generic price pressure.
References
- Statista. (2022). Global calcium channel blocker market size.
- IMS Health. (2023). US prescription drug market analysis.
- FDA. (2021). Patent expiration data for cardiovascular drugs.
- MarketWatch. (2023). Price trends for generic cardiovascular medications.
- GlobalData. (2022). Emerging markets cardiovascular drug outlook.
